Eckert & Ziegler: Revenue Growth, Stable Earnings
The Radiopharmaceutical segment showed the strongest growth in the half year with an increase in sales of 30% over last year's period, to 3.1 million EUR. Sales in the Therapy segment rose by 19% to 10.4 million EUR. Due to outstanding developments in industrial products and raw isotopes, sales in the Nuclear Imaging and Industry segment grew by 8% to 12.9 million EUR, despite the unfavorable progression of the exchange rate with the dollar.
The development shown by the business year thus far meets the expectations of the Board, with the result that the Board continues to anticipate a result of 2.8 million EUR (0.90 EUR per share) before special and one-time effects for the 2007 business year. Due to the 2008 German corporate tax reform, however, a non-monetary burden of 0.8 million EUR (0.25 EUR per share) is expected. Further details on the interim results will be provided in the quarterly report to be released today.
Press releases you might also be interested in
Weitere Informationen zum Thema "Research / Development":
Zendesk stellt Guide Enterprise vor
Mit Guide Enterprise will Zendesk Wissenslücken im Kundenservice schließen. Die KI-gestützte Self-Service-Lösung ist für den Einsatz in Großunternehmen konzipiert.Weiterlesen